Earnings Call Summary | Akoya Biosciences(AKYA.US) Q4 2023 Earnings Conference
Earnings Call Summary | Akoya Biosciences(AKYA.US) Q4 2023 Earnings Conference
The following is a summary of the Akoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call Transcript:
以下是Akoya Biosciences, Inc.（AKYA）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Akoya's Q4 2023 revenue hit $26.5 million and yearly revenue closed at $96.6 million, marking a 29% annual growth.
Gross margin achieved in Q4 was 62.7%.
2024 forecasts predict substantial top-line growth and margin expansion.
Operating expenses in 2023 grew just 4% from the previous year.
Akoya plans to reach operating cash flow breakeven by end of 2024.
Akoya的2023年第四季度收入達到2650萬美元，年收入收於9,660萬美元，年增長29％。
第四季度實現的毛利率爲62.7％。
2024年的預測預測預測收入將大幅增長，利潤率將擴大。
2023年的運營支出僅比上年增長了4％。
Akoya計劃在2024年底之前實現運營現金流盈虧平衡。
Business Progress:
業務進展：
Akoya's installed instruments cover the spectrum of spatial biology markets, totalling 1,200 units.
Strategic partnerships with Thermo Fisher and Enable Medicine targeted advancement of spatial multiomic workflows.
New launches, PhenoCycler-Fusion 2.0 and PhenoImager HT 2.0, significantly enhanced their platforms' capabilities.
For 2024, extension of applications and improved workflow efficiencies aim to drive reagent revenue growth and cost-effectiveness.
The company foresees continued geographical trend and substantial reagent sector growth into 2024, with a plan to reach operating cash flow breakeven, aided by reagents growth and margin expansion.
Akoya安裝的儀器涵蓋了空間生物學市場的各個領域，共計1,200臺。
與賽默飛世爾和Enable Medicine的戰略合作伙伴關係旨在推進空間多組學工作流程。
新推出的Phenocycler-Fusion 2.0和PhenoImager HT 2.0顯著增強了其平台的能力。
2024年，擴大應用範圍和提高工作流程效率旨在推動試劑收入增長和成本效益。
該公司預計，到2024年，試劑行業將繼續保持地理趨勢，並計劃在試劑增長和利潤擴張的幫助下實現運營現金流盈虧平衡。
More details: Akoya Biosciences IR
更多詳情： Akoya 生物科學紅外線
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。